210 related articles for article (PubMed ID: 22782294)
1. Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis.
Drucker AM; Wu S; Dang CT; Lacouture ME
Breast Cancer Res Treat; 2012 Sep; 135(2):347-54. PubMed ID: 22782294
[TBL] [Abstract][Full Text] [Related]
2. Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.
Chung C; Lam MS
Am J Health Syst Pharm; 2013 Sep; 70(18):1579-87. PubMed ID: 23988598
[TBL] [Abstract][Full Text] [Related]
3. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
De Mattos-Arruda L; Cortes J
Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
[TBL] [Abstract][Full Text] [Related]
4. Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
Kawajiri H; Takashima T; Kashiwagi S; Noda S; Onoda N; Hirakawa K
Expert Rev Anticancer Ther; 2015 Jan; 15(1):17-26. PubMed ID: 25494663
[TBL] [Abstract][Full Text] [Related]
5. Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial.
R Ferreira A; Ferreira S; Lambertini M; Maurer C; Martel S; Costa L; Ponde N; de Azambuja E
Eur J Cancer; 2021 Feb; 144():351-359. PubMed ID: 33388492
[TBL] [Abstract][Full Text] [Related]
6. Pertuzumab in HER2-positive breast cancer.
Sendur MA; Aksoy S; Altundag K
Curr Med Res Opin; 2012 Oct; 28(10):1709-16. PubMed ID: 22953713
[TBL] [Abstract][Full Text] [Related]
7. [Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers].
Sabatier R; Gonçalves A
Bull Cancer; 2014; 101(7-8):765-71. PubMed ID: 25091659
[TBL] [Abstract][Full Text] [Related]
8. Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer.
O'Sullivan CC; Swain SM
Expert Opin Biol Ther; 2013 May; 13(5):779-90. PubMed ID: 23530718
[TBL] [Abstract][Full Text] [Related]
9. Pertuzumab: development beyond breast cancer.
Barthélémy P; Leblanc J; Goldbarg V; Wendling F; Kurtz JE
Anticancer Res; 2014 Apr; 34(4):1483-91. PubMed ID: 24692675
[TBL] [Abstract][Full Text] [Related]
10. First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
Blumenthal GM; Scher NS; Cortazar P; Chattopadhyay S; Tang S; Song P; Liu Q; Ringgold K; Pilaro AM; Tilley A; King KE; Graham L; Rellahan BL; Weinberg WC; Chi B; Thomas C; Hughes P; Ibrahim A; Justice R; Pazdur R
Clin Cancer Res; 2013 Sep; 19(18):4911-6. PubMed ID: 23801166
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
12. Pertuzumab: optimizing HER2 blockade.
Metzger-Filho O; Winer EP; Krop I
Clin Cancer Res; 2013 Oct; 19(20):5552-6. PubMed ID: 23942091
[TBL] [Abstract][Full Text] [Related]
13. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.
Phillips GD; Fields CT; Li G; Dowbenko D; Schaefer G; Miller K; Andre F; Burris HA; Albain KS; Harbeck N; Dieras V; Crivellari D; Fang L; Guardino E; Olsen SR; Crocker LM; Sliwkowski MX
Clin Cancer Res; 2014 Jan; 20(2):456-68. PubMed ID: 24097864
[TBL] [Abstract][Full Text] [Related]
14. Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials.
Hao S; Tian W; Gao B; Jiang Y; Zhang X; Zhang S; Guo L; Zhao J; Zhang G; Hu C; Yan J; Luo D
Oncotarget; 2017 Mar; 8(12):19923-19933. PubMed ID: 28199966
[TBL] [Abstract][Full Text] [Related]
15. Pertuzumab: a new anti-HER2 drug in the management of women with breast cancer.
Dawood S; Sirohi B
Future Oncol; 2015; 11(6):923-31. PubMed ID: 25760974
[TBL] [Abstract][Full Text] [Related]
16. Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials.
Shameem R; Lacouture M; Wu S
Acta Oncol; 2015 Jan; 54(1):124-32. PubMed ID: 24914484
[TBL] [Abstract][Full Text] [Related]
17. Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis.
Su X; Lacouture ME; Jia Y; Wu S
Oncology; 2009; 77(2):124-33. PubMed ID: 19622903
[TBL] [Abstract][Full Text] [Related]
18. Pertuzumab: a new targeted therapy for HER2-positive metastatic breast cancer.
Malenfant SJ; Eckmann KR; Barnett CM
Pharmacotherapy; 2014 Jan; 34(1):60-71. PubMed ID: 23918291
[TBL] [Abstract][Full Text] [Related]
19. Pertuzumab for the treatment of breast cancer: a safety review.
Gao J; Swain SM
Expert Opin Drug Saf; 2016 Jun; 15(6):853-63. PubMed ID: 26982349
[TBL] [Abstract][Full Text] [Related]
20. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.
Baselga J; Swain SM
Clin Breast Cancer; 2010 Dec; 10(6):489-91. PubMed ID: 21147694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
